Abivax received ANSM and ethics committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized phase 2b/3 clinical trial
On May 14, 2020 Abivax announced it had received clearance from Franceメs National Agency for the Safety of…